亚洲慢性病毒性肝炎患者肝纤维化预测新的无创指数

StephenW

Sci Rep. 2017 Jun 12;7(1):3259. doi: 10.1038/s41598-017-03589-w.
New noninvasive index for predicting liver fibrosis in Asian patients with chronic viral hepatitis.Wang HW1, Peng CY2,3, Lai HC1,4, Su WP1, Lin CH1, Chuang PH1, Chen SH1,5, Chen CH1, Hsu WF1, Huang GT1,5.
Author information
AbstractWe developed an optimal noninvasive index comprising routine laboratory parameters for predicting cirrhosis in chronic hepatitis B (CHB) and chronic hepatitis C (CHC) patients. This study included 992 CHB patients and 1,284 CHC patients who received liver biopsy. We developed the new index, named modified Fibrosis-4 (mFIB-4) according to four independent variables of the model: age, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count. The formula of the mFIB-4 index is 10 × Age(years) × AST(U/L)/Platelet count(109/L) × ALT(U/L). For predicting cirrhosis, the bootstrap areas under the receiver operating characteristic curve for platelet count, AST/ALT ratio (AAR), AAR/platelet ratio index (AARPRI), AST/platelet ratio index (APRI), FIB-4, Pohl score, age-platelet (AP) index, Lok index, fibrosis quotient (FibroQ), and mFIB-4 were 0.7680, 0.7400, 0.8070, 0.6090, 0.7690, 0.6990, 0.7850, 0.7960, 0.8110, and 0.8070 in CHB patients, and 0.8170, 0.7210, 0.8400, 0.7310, 0.8310, 0.6730, 0.8220, 0.8440, 0.8570, and 0.8480 in CHC patients, respectively. FibroQ and mFIB-4 exhibited the highest diagnostic performance levels for liver cirrhosis in CHB and CHC despite the inclusion of the international normalised ratio in the formulation of FibroQ. Thus, mFIB-4 is a simple, inexpensive, and readily available method for assessing the liver fibrosis stage of Asian patients with CHB or CHC.


PMID:28607450DOI:10.1038/s41598-017-03589-w

StephenW

Sci Rep。2017 Jun 12; 7（1）：3259。 doi：10.1038 / s41598-017-03589-w。
亚洲慢性病毒性肝炎患者肝纤维化预测新的无创指数。
王HW1，彭CY2,3，赖HC1,4，苏WP1，林CH1，创PH1，陈SH1,5，陈CH1，徐WF1，黄GT1,5。
作者信息
抽象

我们开发了一种最佳的非侵入性指数，包括预测慢性乙型肝炎（CHB）和慢性丙型肝炎（CHC）患者肝硬化的常规实验室参数。本研究包括992例CHB患者和1,284例接受肝活检的CHC患者。根据模型的四个独立变量：年龄，天冬氨酸氨基转移酶（AST），丙氨酸氨基转移酶（ALT）和血小板计数，我们开发了名为改良的纤维化-4（mFIB-4）的新指标。 mFIB-4指数的公式为10×年龄（AST）×AST（U / L）/血小板计数（109 / L）×ALT（U / L）。对于预测肝硬化，血小板计数，AST / ALT比（AAR），AAR /血小板比指数（AARPRI），AST /血小板比指数（APRI），FIB-4，Pohl评分的接受者手术特征曲线下的引导区域， CHB患者的年龄 - 血小板（AP）指数，Lok指数，纤维化商（FibroQ）和mFIB-4分别为0.7680,0.772,0.8070,0.6090，0.7690，0.6990，0.7850，0.7960，0.8110和0.8070， ，0.8400,0.7310,0.8310,0.67030,0.82020,0.88440,0.8570和0.8480。 FibroQ和mFIB-4在CHB和CHC中表现出肝硬化的最高诊断性能水平，尽管在FibroQ制剂中纳入国际标准化比例。因此，mFIB-4是用于评估亚洲CHB或CHC患者的肝纤维化阶段的简单，便宜且易于获得的方法。

结论：
    28607450
DOI：
    10.1038 / s41598-017-03589-W

StephenW

https://www.nature.com/articles/s41598-017-03589-w